Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN

Zhang,Guanhua; Gan,Ye-Hua

doi:10.3892/or.2017.5981

Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN

Authors:
- Guanhua Zhang
- Ye-Hua Gan
View Affiliations

Affiliations: Central Laboratory, Peking University School and Hospital of Stomatology, Haidian, Beijing 100081, P.R. China
Published online on: September 21, 2017 https://doi.org/10.3892/or.2017.5981
Pages: 2657-2666
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapy is one of the most effective non-surgical treatments for various types of tumor. Identifying different combinations of antitumor agents that can produce synergistic antitumor effects remains an important clinical strategy. In the present study, we showed that the combination of histone deacetylase 6 (HDAC6) inhibitor tubastatin A together with cyclooxygenase-2 (COX-2) inhibitor celecoxib resulted in synergistic antitumor effects in CAL 27 and SACC-83 cells. Treatment with celecoxib alone promoted the membrane translocation of phosphatase and tensin homolog (PTEN), indicating PTEN activation, and consequently led to protein kinase B (AKT) dephosphorylation (inactivation). Similarly, treatment with an HDAC6 inhibitor alone promoted PTEN membrane translocation and correspondingly dephosphorylated AKT. The combination of celecoxib and an HDAC6 inhibitor synergistically increased PTEN membrane translocation and inactivated AKT. Moreover, celecoxib enhanced the HDAC6 inhibitor-induced antitumor effects in PTEN-deficient U-87 MG cells that had been stably transfected with wild-type PTEN, but not in the same cell line stably transfected with mutant PTEN-K163R, which cannot be activated by HDAC6 inhibitors. In summary, the results indicated that the COX-2 inhibitor celecoxib enhanced the HDAC6 inhibitor-induced antitumor effects by activating the PTEN/AKT signaling pathway.

View Figures

View References

1	Liu T, Liu X and Li W: Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy. Oncotarget. 7:40800–40815. 2016. View Article : Google Scholar : PubMed/NCBI
2	Volm M and Efferth T: Prediction of Cancer Drug Resistance and Implications for Personalized Medicine. Front Oncol. 5:2822015. View Article : Google Scholar : PubMed/NCBI
3	Damaskos C, Karatzas T, Nikolidakis L, Kostakis ID, Karamaroudis S, Boutsikos G, Damaskou Z, Kostakis A and Kouraklis G: Histone deacetylase (HDAC) inhibitors: Current evidence for therapeutic activities in pancreatic cancer. Anticancer Res. 35:3129–3135. 2015.PubMed/NCBI
4	Bukowska B, Gajek A and Marczak A: Two drugs are better than one. A short history of combined therapy of ovarian cancer. Contemp Oncol. 19:350–353. 2015.
5	Drazic A, Myklebust LM, Ree R and Arnesen T: The world of protein acetylation. Biochim Biophys Acta. 1864:1372–1401. 2016. View Article : Google Scholar : PubMed/NCBI
6	Zhang C, Zhong JF, Stucky A, Chen XL, Press MF and Zhang X: Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia. Clin Epigenetics. 7:1172015. View Article : Google Scholar : PubMed/NCBI
7	Mathias RA, Guise AJ and Cristea IM: Post-translational modifications regulate class IIa histone deacetylase (HDAC) function in health and disease. Mol Cell Proteomics. 14:456–470. 2015. View Article : Google Scholar : PubMed/NCBI
8	Zhang H, Shang YP, Chen HY and Li J: Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatol Res. Jul 26–2016.(Epub ahead of print). doi: 10.1111/hepr.12757.
9	Gan YH and Zhang S: PTEN/AKT pathway involved in histone deacetylases inhibitor induced cell growth inhibition and apoptosis of oral squamous cell carcinoma cells. Oral Oncol. 45:e150–e154. 2009. View Article : Google Scholar : PubMed/NCBI
10	Huang WJ, Liang YC, Chuang SE, Chi LL, Lee CY, Lin CW, Chen AL, Huang JS, Chiu CJ, Lee CF, et al: NBM-HD-1: A novel histone deacetylase inhibitor with anticancer activity. Evid Based Complement Alternat Med. 2012:7814172012. View Article : Google Scholar : PubMed/NCBI
11	Manal M, Chandrasekar MJ, Priya J Gomathi and Nanjan MJ: Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorg Chem. 67:18–42. 2016. View Article : Google Scholar : PubMed/NCBI
12	Ossenkoppele GJ, Lowenberg B, Zachee P, Vey N, Breems D, Van de Loosdrecht AA, Davidson AH, Wells G, Needham L, Bawden L, et al: A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies. Br J Haematol. 162:191–201. 2013. View Article : Google Scholar : PubMed/NCBI
13	Witt O, Deubzer HE, Milde T and Oehme I: HDAC family: What are the cancer relevant targets? Cancer Lett. 277:8–21. 2009. View Article : Google Scholar : PubMed/NCBI
14	Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, et al: Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol. 28:1688–1701. 2008. View Article : Google Scholar : PubMed/NCBI
15	McConkey DJ, White M and Yan W: HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer. Adv Cancer Res. 116:131–163. 2012. View Article : Google Scholar : PubMed/NCBI
16	Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL, Yoshida M, et al: Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene. 24:4531–4539. 2005. View Article : Google Scholar : PubMed/NCBI
17	Meng Z, Jia LF and Gan YH: PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition. Oncogene. 35:2333–2344. 2016. View Article : Google Scholar : PubMed/NCBI
18	Gu J, Wang D, Zhang J, Zhu Y, Li Y, Chen H, Shi M, Wang X, Shen B, Deng X, et al: GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. Cancer Lett. 380:434–441. 2016. View Article : Google Scholar : PubMed/NCBI
19	Milella M, Falcone I, Conciatori F, Incani U Cesta, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F, et al: PTEN: Multiple functions in human malignant tumors. Front Oncol. 5:242015. View Article : Google Scholar : PubMed/NCBI
20	Tesio M, Trinquand A, Macintyre E and Asnafi V: Oncogenic PTEN functions and models in T-cell malignancies. Oncogene. 35:3887–3896. 2016. View Article : Google Scholar : PubMed/NCBI
21	Vazquez F, Matsuoka S, Sellers WR, Yanagida T, Ueda M and Devreotes PN: Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. Proc Natl Acad Sci USA. 103:pp. 3633–3638. 2006; View Article : Google Scholar : PubMed/NCBI
22	Meng Z and Gan YH: Activating PTEN by COX-2 inhibitors antagonizes radiation-induced AKT activation contributing to radiosensitization. Biochem Biophys Res Commun. 460:198–204. 2015. View Article : Google Scholar : PubMed/NCBI
23	Ke J, Yang Y, Che Q, Jiang F, Wang H, Chen Z, Zhu M, Tong H, Zhang H, Yan X, et al: Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer. Tumour Biol. 37:12203–12211. 2016. View Article : Google Scholar : PubMed/NCBI
24	Gan L, Qiu Z, Huang J, Li Y, Huang H, Xiang T, Wan J, Hui T, Lin Y, Li H, et al: Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway. Int J Biol Sci. 12:1533–1543. 2016. View Article : Google Scholar : PubMed/NCBI
25	Salehifar E and Hosseinimehr SJ: The use of cyclooxygenase-2 inhibitors for improvement of efficacy of radiotherapy in cancers. Drug Discov Today. 21:654–662. 2016. View Article : Google Scholar : PubMed/NCBI
26	Vosooghi M and Amini M: The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies. Expert Opin Drug Discov. 9:255–267. 2014. View Article : Google Scholar : PubMed/NCBI
27	Liu R, Xu KP and Tan GS: Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed. Eur J Pharmacol. 769:127–133. 2015. View Article : Google Scholar : PubMed/NCBI
28	Wang X, Li G, Wang A, Zhang Z, Merchan JR and Halmos B: Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells. Mol Carcinog. 52:218–228. 2013. View Article : Google Scholar : PubMed/NCBI
29	Gioanni J, Fischel JL, Lambert JC, Demard F, Mazeau C, Zanghellini E, Ettore F, Formento P, Chauvel P, Lalanne CM, et al: Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: Establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol. 24:1445–1455. 1988. View Article : Google Scholar : PubMed/NCBI
30	Li SL: Establishment of a human cancer cell line from adenoid cystic carcinoma of the minor salivary gland. Zhonghua Kou Qiang Yi Xue Za Zhi. 25(29-31): 621990.(In Chinese).
31	Wu Y, Zhu Y, Li S, Zeng M, Chu J, Hu P, Li J, Guo Q, Lv XB and Huang G: Terrein performs antitumor functions on esophageal cancer cells by inhibiting cell proliferation and synergistic interaction with cisplatin. Oncol Lett. 13:2805–2810. 2017.PubMed/NCBI
32	Kou XX, Hao T, Meng Z, Zhou YH and Gan YH: Acetylated Sp1 inhibits PTEN expression through binding to PTEN core promoter and recruitment of HDAC1 and promotes cancer cell migration and invasion. Carcinogenesis. 34:58–67. 2013. View Article : Google Scholar : PubMed/NCBI
33	Abdelrahim M and Safe S: Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol. 68:317–329. 2005.PubMed/NCBI